Evidence-based diagnostic strategies for evaluating suspected allergic rhinitis

被引:73
作者
Gendo, K
Larson, EB
机构
[1] Univ Washington, Grp Hlth Cooperat, Ctr Hlth Studies, Seattle, WA 98101 USA
[2] Univ Washington, NW Asthma & Allergy Ctr, Seattle, WA 98101 USA
关键词
D O I
10.7326/0003-4819-140-4-200402170-00010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Allergic rhinitis is an increasingly common disease, with a prevalence of at least 10% to 25% in the United States. Diagnostic allergy tests, such as skin tests and in vitro tests, can assist clinicians in determining whether nasal symptoms are allergic in origin. In addition, safe and effective medications are available to treat allergic rhinitis. The initial strategy should be to determine whether patients should undergo diagnostic testing or receive empirical treatment. This paper reviews the test characteristics of the history, skin tests, and in vitro tests in diagnosing allergic rhinitis from the perspective of decision thresholds. A combination of pertinent medical history features in a practice with a high baseline prevalence of allergic rhinitis justifies the common practice of empirical treatment since allergy medication has minimal toxicity and side effects. The situation is more complex when the patient needs a diagnostic test, because reported sensitivities and specificities of skin tests and in vitro tests vary widely. As a result, it is difficult to calculate the post-test probability of allergic rhinitis with any confidence. The decision to initiate diagnostic testing must rely on clinical judgment to select patients who would benefit most from determining their allergic status while minimizing unnecessary testing and medications. Diagnosing allergy to a specific antigen allows patients to avoid the allergen and makes them candidates for allergen immunotherapy, which can decrease the need for medications.
引用
收藏
页码:278 / 289
页数:12
相关论文
共 55 条
[1]   The score for allergic rhinitis (SFAR): a simple and valid assessment method in population studies [J].
Annesi-Maesano, I ;
Didier, A ;
Klossek, M ;
Chanal, I ;
Moreau, D ;
Bousquet, J .
ALLERGY, 2002, 57 (02) :107-114
[2]  
BENT S, 1998, EVIDENCE BASED MED F, P59
[3]  
Bernstein IL, 1995, ANN ALLERG ASTHMA IM, V75, P543
[4]   DOUBLE-BLIND, PLACEBO-CONTROLLED IMMUNOTHERAPY WITH MIXED GRASS-POLLEN ALLERGOIDS .2. COMPARISON BETWEEN PARAMETERS ASSESSING THE EFFICACY OF IMMUNOTHERAPY [J].
BOUSQUET, J ;
MAASCH, H ;
MARTINOT, B ;
HEJJAOUI, A ;
WAHL, R ;
MICHEL, FB .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1988, 82 (03) :439-446
[5]   NASAL CHALLENGE WITH POLLEN GRAINS, SKIN-PRICK TESTS AND SPECIFIC IGE IN PATIENTS WITH GRASS-POLLEN ALLERGY [J].
BOUSQUET, J ;
LEBEL, B ;
DHIVERT, H ;
BATAILLE, Y ;
MARTINOT, B ;
MICHEL, FB .
CLINICAL ALLERGY, 1987, 17 (06) :529-536
[6]  
Bousquet J., 2002, Allergy (Copenhagen), V57, P841, DOI 10.1034/j.1398-9995.2002.23625.x
[7]  
BROOKS GD, 2002, PATTERSONS ALLERGIC, P81
[8]  
Charpin D, 1996, ALLERGY, V51, P293, DOI 10.1111/j.1398-9995.1996.tb00088.x
[9]  
CLARKE PS, 1987, ANN ALLERGY, V59, P25
[10]  
Crobach MJJS, 1998, SCAND J PRIM HEALTH, V16, P30